JP2010500973A - アルギナーゼ濃度／活性の改善 - Google Patents

アルギナーゼ濃度／活性の改善 Download PDF

Info

Publication number
JP2010500973A
JP2010500973A JP2009521781A JP2009521781A JP2010500973A JP 2010500973 A JP2010500973 A JP 2010500973A JP 2009521781 A JP2009521781 A JP 2009521781A JP 2009521781 A JP2009521781 A JP 2009521781A JP 2010500973 A JP2010500973 A JP 2010500973A
Authority
JP
Japan
Prior art keywords
compound
composition
cocoa
subject
epicatechin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009521781A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010500973A5 (enExample
Inventor
エイチ シュミッツ，ハロルド
エル クウィク−ウリベ，キャサリン
シュレーター，ハーゲン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Mars Inc
Original Assignee
University of California
Mars Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, Mars Inc filed Critical University of California
Publication of JP2010500973A publication Critical patent/JP2010500973A/ja
Publication of JP2010500973A5 publication Critical patent/JP2010500973A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2009521781A 2006-07-21 2007-07-20 アルギナーゼ濃度／活性の改善 Pending JP2010500973A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83268406P 2006-07-21 2006-07-21
PCT/US2007/016504 WO2008011173A2 (en) 2006-07-21 2007-07-20 Improvement of arginase levels/activity

Publications (2)

Publication Number Publication Date
JP2010500973A true JP2010500973A (ja) 2010-01-14
JP2010500973A5 JP2010500973A5 (enExample) 2010-09-09

Family

ID=38957417

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009521781A Pending JP2010500973A (ja) 2006-07-21 2007-07-20 アルギナーゼ濃度／活性の改善

Country Status (9)

Country Link
US (3) US20080021097A1 (enExample)
EP (2) EP2438915A1 (enExample)
JP (1) JP2010500973A (enExample)
CN (1) CN101516407B (enExample)
AU (1) AU2007275561B2 (enExample)
CA (1) CA2657915A1 (enExample)
IL (1) IL196480A0 (enExample)
RU (2) RU2469742C2 (enExample)
WO (1) WO2008011173A2 (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085947A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット及びアルギナーゼ関連疾患検出キット
WO2017086421A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法
JPWO2017086421A1 (ja) * 2015-11-18 2018-10-18 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法
JP2018194389A (ja) * 2017-05-16 2018-12-06 東京応化工業株式会社 尿素の測定方法及び尿素検出キット

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2418949A4 (en) * 2009-04-17 2012-11-28 Cardero Therapeutics Inc METHOD AND COMPOSITIONS FOR THE TREATMENT OF ISCHEMIC ILLNESSES AND SUFFERING IN CONNECTION WITH THE MITOCHONDRY FUNCTION
FR2973234A1 (fr) * 2011-03-31 2012-10-05 Oreal Utilisation cosmetique d'inhibiteur d'arginase, comme agent pour freiner la chute des cheveux, des sourcils et/ou des cils
JP2014521702A (ja) * 2011-08-05 2014-08-28 カーデロ セラピューティクス インコーポレイテッド フラボノイド化合物
US9266260B2 (en) * 2011-12-20 2016-02-23 Massachusetts Institute Of Technology Precision continuous stamp casting method for roll-based soft lithography
AU2013301215B2 (en) * 2012-08-07 2016-06-30 Indus Biotech Private Limited A method of managing diabetic foot ulcers, pressure ulcers, venous leg ulcers and associated complication
US11229685B2 (en) 2013-01-29 2022-01-25 Case Western Reserve University Fungal iron acquisition inhibitors and uses thereof
WO2016046375A1 (en) * 2014-09-25 2016-03-31 Institut National De La Sante Et De La Recherche Medicale (Inserm) Theobroma cacao extract for use in the treatment or prevention of receptor tyrosine kinases related disorders
US20160199463A1 (en) * 2014-12-15 2016-07-14 The Johns Hopkins University Hdac2 defends vascular endothelium from injury
CN107815370A (zh) * 2017-11-17 2018-03-20 华坪县腾辉酒业有限公司 一种蓝莓露酒及其制备方法
US11269896B2 (en) 2019-09-10 2022-03-08 Fujitsu Limited System and method for automatic difficulty level estimation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505864A (ja) * 1998-03-12 2002-02-26 マーズ インコーポレーテッド 窒素酸化物の生成を促進するためにポリフェノールおよびｌ−アルギニンを含有する製品
WO2003032969A2 (en) * 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
WO2005123096A2 (en) * 2004-06-14 2005-12-29 Mars, Incorporated Compositions and methods of use of dimer digallates
WO2006049258A1 (ja) * 2004-11-04 2006-05-11 University Of Tsukuba 発酵茶から抽出された高分子ポリフェノール、ミトコンドリア病治療剤、糖尿病予防・治療剤、並びに飲食物

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5554645A (en) 1994-10-03 1996-09-10 Mars, Incorporated Antineoplastic cocoa extracts and methods for making and using the same
US6469053B1 (en) * 1996-04-02 2002-10-22 Mars Incorporated Use of procyanidins in the maintenance of vascular health and modulation of the inflammatory response
US6297273B1 (en) 1996-04-02 2001-10-02 Mars, Inc. Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions
US6312753B1 (en) 1996-09-06 2001-11-06 Mars, Incorporated Cocoa components, edible products having enriched polyphenol content, methods of making same and medical uses
US6015913A (en) 1996-09-06 2000-01-18 Mars, Incorporated Method for producing fat and/or solids from cocoa beans
US6207842B1 (en) 1997-10-09 2001-03-27 Mars Incorporated Process for preparing procyanidin(4-6 or 4-8) oligomers and their derivatives
EP1049660A1 (en) * 1997-10-10 2000-11-08 The Trustees Of The University Of Pennsylvania Compositions and methods for inhibiting arginase activity
US6805883B2 (en) * 1998-03-12 2004-10-19 Mars, Incorporated Food products containing polyphenol(s) and L-arginine to stimulate nitric oxide
US6156912A (en) 1999-04-09 2000-12-05 Mars, Incorporated 88, 66, and 68 catechin and epicatechin dimers and methods for their preparation
US7015338B1 (en) 1999-04-15 2006-03-21 Mars Incorporated Synthetic methods for preparing procyanidin oligomers
JP2001013453A (ja) * 1999-06-28 2001-01-19 Canon Inc 光学装置
EP1072265A1 (en) * 1999-07-20 2001-01-31 MEDIS S.r.l. Medical Infusion Systems Use of plant polyphenols for treating iron overload
JP4112764B2 (ja) * 1999-11-19 2008-07-02 株式会社伊勢半 皮膚外用剤
US6627232B1 (en) 2000-06-09 2003-09-30 Mars Incorporated Method for extracting cocoa procyanidins
US7514107B2 (en) * 2002-03-21 2009-04-07 Mars, Incorporated Treatment of diseases involving defective gap junctional communication
US20040115285A1 (en) * 2002-12-13 2004-06-17 Peter Rohdewald Method of normalizing glucose levels in blood of patients with diabetes mellitus by oral administration of proanthocyanidins containing plant extracts
US20060293258A1 (en) * 2005-06-23 2006-12-28 Peter Rohdewald Method and composition to treat skin ulcers
US20060293259A1 (en) * 2005-06-28 2006-12-28 Mars, Incorporated Compositions and methods of use of derivatized flavanols
WO2007002851A2 (en) * 2005-06-29 2007-01-04 Mars, Incorporated Thermally-processed cocoa products useful for vascular health improvement
TW200825084A (en) * 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002505864A (ja) * 1998-03-12 2002-02-26 マーズ インコーポレーテッド 窒素酸化物の生成を促進するためにポリフェノールおよびｌ−アルギニンを含有する製品
WO2003032969A2 (en) * 2001-10-15 2003-04-24 National Research Council Of Canada Anti-glycation agents for preventing age-, diabetes-, and smoking-related complications
WO2005123096A2 (en) * 2004-06-14 2005-12-29 Mars, Incorporated Compositions and methods of use of dimer digallates
WO2006049258A1 (ja) * 2004-11-04 2006-05-11 University Of Tsukuba 発酵茶から抽出された高分子ポリフェノール、ミトコンドリア病治療剤、糖尿病予防・治療剤、並びに飲食物

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6012050098; Ｐｒｏｃ．　Ｎａｔｌ．　Ａｃａｄ．　Ｓｃｉ． Ｖｏｌ．１０３　Ｎｏ．４, 200601, ｐｐ．１０２４-１０２９ *
JPN6012050099; Ｃｌｉｎ．　Ｄｅｖ．　Ｉｍｍｕｎｏｌ． Ｖｏｌ．１２　Ｎｏ．１, 2005, ｐｐ．２７-３４ *
JPN6012050100; Ｆｉｓｈ．　Ｓｃｉ． Ｖｏｌ．６６, 2000, ｐｐ．３２１-３２６ *
JPN6012050101; Ａｍ．　Ｊ．　Ｐａｔｈｏｌ． Ｖｏｌ．１６５　Ｎｏ．１, 2004, ｐｐ．２９９-３０７ *
JPN6013027979; 第５０回　日本栄養・食糧学会大会講演要旨集 , 1996, ｐ．５３ *
JPN6013027981; Ｅｘｐ．　Ｂｉｏｌ．　Ｍｅｄ． Ｖｏｌ．２２９, 2004, ｐｐ．３３-３９ *
JPN6013027983; Ｊ．　Ｐｈｙｓｉｏｌ．　Ｐｈａｒｍａｃｏｌ． Ｖｏｌ．５２　Ｎｏ．３, 2001, ｐｐ．４８３-４８８ *
JPN6013027987; Ｃｕｒｒ．　Ｈｙｐｅｒｔｅｎｓ．　Ｒｅｐ． Ｖｏｌ．８　Ｎｏ．１, 200604, ｐｐ．５４-５９ *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017085947A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット及びアルギナーゼ関連疾患検出キット
WO2017086421A1 (ja) * 2015-11-18 2017-05-26 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法
JPWO2017086421A1 (ja) * 2015-11-18 2018-10-18 東京応化工業株式会社 アルギナーゼ活性の測定方法、アルギナーゼ活性の検出キット、アルギナーゼ関連疾患検出キット、及びアルギナーゼの阻害剤又は活性剤のスクリーニング方法
JP2018194389A (ja) * 2017-05-16 2018-12-06 東京応化工業株式会社 尿素の測定方法及び尿素検出キット

Also Published As

Publication number Publication date
CN101516407A (zh) 2009-08-26
US20120015053A1 (en) 2012-01-19
AU2007275561A1 (en) 2008-01-24
WO2008011173A2 (en) 2008-01-24
WO2008011173A3 (en) 2008-07-03
IL196480A0 (en) 2009-11-18
CN101516407B (zh) 2012-03-21
RU2012137517A (ru) 2014-03-10
RU2469742C2 (ru) 2012-12-20
AU2007275561B2 (en) 2013-12-19
EP2068941A2 (en) 2009-06-17
EP2438915A1 (en) 2012-04-11
EP2068941A4 (en) 2009-09-30
US20110257119A1 (en) 2011-10-20
CA2657915A1 (en) 2008-01-24
RU2009106041A (ru) 2010-08-27
US20080021097A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
JP2010500973A (ja) アルギナーゼ濃度／活性の改善
JP4970690B2 (ja) 血管の健康状態を改善するための組成物および方法
US20190269715A1 (en) Compositions and method of use of a-type procyanidins
US7115656B2 (en) Compositions for, and methods of, anti-platelet therapy
JP2014028823A (ja) 皮膚の保護および改善
JP2009501161A (ja) 血管系の健康改善に有用な熱処理されたカカオ製品
JPWO2012121140A1 (ja) 成長ホルモン分泌促進剤
BR112020016923A2 (pt) Método para reverter ou atenuar lesão, ou fraqueza ou perda óssea, ou para evitar fraturas em um indivíduo, e, composição
JP6149290B2 (ja) 末梢血管の血管拡張の誘導
MX2013006503A (es) Compuestos que tienen influencia en la absorcion y metabolismo del acido graso y la produccion de agentes inflamatorios y metodos para aislarlos de productos de cacao.
US20070004652A1 (en) Treatment of occlusive thrombosis
US20050277600A1 (en) Compositions and methods of use of dimer digallates
US20090286869A1 (en) Flavanols and B-Type Procyanidins and Inflammation
WO2007084648A2 (en) Mixed 4→6 procyanidin dimers and their use
CN119013011A (zh) 用于代谢健康的ampk活化剂（cbda）和sglt2抑制剂
CN117940141A (zh) 用于预防、减轻或治疗肌无力相关疾病的包括芹菜籽提取物作为活性成分的组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100720

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110223

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120925

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130911

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130919

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131011

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131021

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140401